AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Astrazeneca Plc ended up being:
The company's compound free cash flow growth rate over the past 5.48 years comes in at -0.12%; that's greater than only 13.19% of US stocks we're applying DCF forecasting to.
The company has produced more trailing twelve month cash flow than 89.97% of its sector Healthcare.
Astrazeneca Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 23.73% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
DHR, TFX, ABC, ICUI, and EHC can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Selling pressure on Moderna (MRNA) came to an end on Sept. 8, a week after this “Neutral” rating. Investors are starting to pick out the winners from the losers, betting on the companies poised first to mass-produce a coronavirus vaccine. And although the stock tripled since the start of the...
European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different strategies by two of …
Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Vitamin A Palmitate Market which would mention How the Covid-19 is affecting the Vitamin A Palmitate Industry, Market
Several coronavirus vaccine trials will soon be finished and some of the frontrunners might be deemed safe and effective for emergency use. Health officials from the World Health Organization and Dr. Anthony Fauci warn that the arrival of COVID-19 vaccines won't be enough to reduce the transmission of the illness anytime soon. Fauci says that precautionary measures including face masks, social distancing, and frequent handwashing will need to continue even after vaccines arrive. The FDA will host a significant coronavirus vaccine meeting in just a few weeks, at which point we might find out more details about the progress of experimental drugs that have reached the final phase of testing. Vaccine candidates from AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna have Phase 3 trials underw...